ArticleAnnals of hematology2026
Gray platelet syndrome as a multisystem disorder: immune dysregulation, autoimmunity, and metabolic abnormalities.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gray platelet syndrome (GPS) is a rare inherited platelet disorder caused by defective α-granule biogenesis. Emerging evidence suggests that GPS represents a multisystem disorder with immune and inflammatory manifestations. We report three siblings from a single family with genetically confirmed GPS who presented with lifelong thrombocytopenia and mild to severe bleeding symptoms. Notably, all affected individuals had persistently elevated serum vitamin B12 of unclear etiology. One sibling had concomitant type 1 diabetes mellitus and biopsy confirmed celiac disease. This familial case series highlights the phenotypic heterogeneity of GPS and supports its recognition as a multisystem disorder. The consistent finding of hypercobalaminemia represents a notable but poorly understood feature, while the coexistence of autoimmune disease suggests underlying immune dysregulation related to NBEAL2 deficiency. Gray platelet syndrome may involve metabolic and autoimmune manifestations beyond bleeding. Awareness of these associations is essential for comprehensive evaluation and long-term management of affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.